Vitreous Floaters Confer Increased Risk for Retinal Detachment
via HealthDayFRIDAY, March 27, 2026 -- New-onset vitreous floaters, with or without flashes, confer an increased risk for retinal detachment (RD), according to a study published in the March issue of the Annals of Family Medicine.
Bart van Zon, M.D., from Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a retrospective cohort study involving adults with new-onset floaters or flashes during 2012 to 2021 to examine the absolute and relative risk associated with RD. A total of 1,181 cases were categorized into floaters, flashes and floaters, and flashes.
The researchers found that the incidence of floaters and flashes was 5.5 and 2.7 per 1,000 patient-years, respectively. The absolute risk for RD was 6.1, 4.7, and 8.4 percent for floaters alone, flashes alone, and floaters and flashes, respectively. Absolute risk was increased in association with acute duration (≤14 days) and with many floaters (defined as ≥10 floaters or a cloud/haze/curtain). Compared with flashes alone, the relative risks were significantly increased for acute floaters and flashes, many floaters, and many floaters and flashes (2.39, 4.20, and 6.20, respectively).
"Our results show that floaters (with or without flashes) represent a clinically relevant risk for RD, especially with a recent (acute) onset or if there are many of them," the authors write. "We recommend urgent referral of these patients to confirm or rule out RD."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-28 01:51
Read more
- Health Care Costs Impacting Families' Financial Decisions
- Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
- Study Links State Taxes to COVID Lockdown Decisions
- FDA Warns Novo Nordisk Broke Safety Reporting Rules
- Power Outages May Increase Risk for Hospitalization Among Older U.S. Adults
- Chris Bosh Says He’s 'Lucky To Be Alive' After Sudden Health Scare
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions